| scholarly article | Q13442814 |
| P50 | author | Chia-Lang Hsu | Q57563516 |
| P2093 | author name string | Hsueh-Fen Juan | |
| Chi-Hau Chen | |||
| Ho-Hsiung Lin | |||
| Min-Chuan Huang | |||
| John Huang | |||
| Tzu-Chi Lin | |||
| Syue-Ting Chen | |||
| P2860 | cites work | ARID1A mutations in endometriosis-associated ovarian carcinomas | Q24610484 |
| Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family | Q26864268 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Clear cell carcinoma of the ovary: a review of the literature | Q28265125 | ||
| Type-specific cell line models for type-specific ovarian cancer research | Q28536689 | ||
| Integration of biological networks and gene expression data using Cytoscape | Q28681323 | ||
| Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. | Q34006269 | ||
| Glycosylation defining cancer malignancy: new wine in an old bottle | Q34074081 | ||
| Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin | Q34763642 | ||
| Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival | Q35034722 | ||
| Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review | Q35099083 | ||
| Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling | Q35742375 | ||
| New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. | Q36889642 | ||
| Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
| Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. | Q37196721 | ||
| Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. | Q37485865 | ||
| Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation | Q37660331 | ||
| The extended ppGalNAc-T family and their functional involvement in the metastatic cascade | Q38150732 | ||
| Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. | Q38297113 | ||
| GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity | Q38308686 | ||
| Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown | Q38767655 | ||
| The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded | Q38787667 | ||
| MUC20 promotes aggressive phenotypes of epithelial ovarian cancer cells via activation of the integrin β1 pathway | Q38816028 | ||
| The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. | Q39147421 | ||
| MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer | Q39221819 | ||
| Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor | Q39459644 | ||
| Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis | Q39730101 | ||
| Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance | Q79972618 | ||
| Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited | Q81370832 | ||
| Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma | Q83139511 | ||
| P4510 | describes a project that uses | Cytoscape | Q3699942 |
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 42588-42601 | |
| P577 | publication date | 2017-03-28 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity | |
| P478 | volume | 8 |
| Q58757254 | Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells |
| Q53690855 | GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells. |
| Q94562112 | GALNT6 promotes invasion and metastasis of human lung adenocarcinoma cells through O-glycosylating chaperone protein GRP78 |
| Q60921914 | GALNT6 suppresses progression of colorectal cancer |
| Q49805726 | Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling |
| Q52369544 | Regulation of TNF-Related Apoptosis-Inducing Ligand Signaling by Glycosylation. |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q91890334 | The polypeptide GALNT6 Displays Redundant Functions upon Suppression of its Closest Homolog GALNT3 in Mediating Aberrant O-Glycosylation, Associated with Ovarian Cancer Progression |
Search more.